BRPI0409929A - formulação para tornar uma droga antimicrobiana potente contra organismos normalmente considerados serem resistentes à droga - Google Patents

formulação para tornar uma droga antimicrobiana potente contra organismos normalmente considerados serem resistentes à droga

Info

Publication number
BRPI0409929A
BRPI0409929A BRPI0409929-0A BRPI0409929A BRPI0409929A BR PI0409929 A BRPI0409929 A BR PI0409929A BR PI0409929 A BRPI0409929 A BR PI0409929A BR PI0409929 A BRPI0409929 A BR PI0409929A
Authority
BR
Brazil
Prior art keywords
drug
resistant
agent
normally considered
formulation
Prior art date
Application number
BRPI0409929-0A
Other languages
English (en)
Inventor
Barrett E Rabinow
Randy White
Chong-Son Sun
Joseph Chung Tak Wong
James E Kipp
Mark J Doty
Christine L Rebbeck
Pavlos Papadopoulos
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of BRPI0409929A publication Critical patent/BRPI0409929A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"FORMULAçãO PARA TORNAR UMA DROGA ANTI-MICROBIANA POTENTE CONTRA ORGANISMOS NORMALMENTE CONSIDERADOS SEREM RESISTENTES à DROGA". A presente invenção refere-se a composições de partículas de tamanho submícron a mícron de agentes antimicrobianos. Mais particularmente a invenção refere-se a uma composição de um agente antimicrobiano que torna o agente potente contra organismos normalmente considerados serem resistentes ao agente. A composição compreende uma suspensão aquosa de partículas de tamanho submícron a mícron contendo o agente revestidas com pelo menos um tensoativo selecionado do grupo consistindo em: tensoativos iónicos, tensoativos não-iónicos, tensoativos derivados biologicamente, e aminoácidos e seus derivados. As partículas têm um tamanho de partícula médio de volume pesado de menos que 5 <109>m como medido por difratometria de laser.
BRPI0409929-0A 2003-04-29 2004-04-29 formulação para tornar uma droga antimicrobiana potente contra organismos normalmente considerados serem resistentes à droga BRPI0409929A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46635403P 2003-04-29 2003-04-29
PCT/US2004/013268 WO2004096180A1 (en) 2003-04-29 2004-04-29 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

Publications (1)

Publication Number Publication Date
BRPI0409929A true BRPI0409929A (pt) 2006-04-25

Family

ID=33418369

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409929-0A BRPI0409929A (pt) 2003-04-29 2004-04-29 formulação para tornar uma droga antimicrobiana potente contra organismos normalmente considerados serem resistentes à droga

Country Status (11)

Country Link
EP (1) EP1617818A1 (pt)
JP (1) JP2006525345A (pt)
KR (1) KR20060015553A (pt)
CN (1) CN1794975A (pt)
AU (1) AU2004234003A1 (pt)
BR (1) BRPI0409929A (pt)
CA (1) CA2523151A1 (pt)
MX (1) MXPA05011607A (pt)
NO (1) NO20055616L (pt)
WO (1) WO2004096180A1 (pt)
ZA (1) ZA200508467B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100858508B1 (ko) 2005-12-23 2008-09-12 주식회사 삼양사 아졸계 항진균제를 포함하는 조성물 및 그의 제조방법
JP2009538927A (ja) * 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
DE11853027T1 (de) * 2010-12-30 2014-09-11 Respublikanskoe Gosudarstvennoe Predpriyatie "Nauchnyj Centr Protivoinfekcionnyh Antibakterielles mittel zur behandlung von infektionskrankheiten bakteriellen ursprungs
CN102085176A (zh) * 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
CN102106832A (zh) * 2011-02-12 2011-06-29 华中师范大学 酮康唑纳米混悬剂冻干粉及其制备方法
EP3319608A4 (en) * 2015-07-07 2019-04-03 LifeRaft Biosciences, Inc. POLOXAMER 188 FORMULATIONS WITH REDUCED SODIUM AND METHOD OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2333648C (en) * 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
DE60020382T2 (de) * 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
DK1347747T3 (da) * 2000-12-22 2006-04-10 Baxter Int Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix

Also Published As

Publication number Publication date
CA2523151A1 (en) 2004-11-11
WO2004096180A1 (en) 2004-11-11
MXPA05011607A (es) 2005-12-15
KR20060015553A (ko) 2006-02-17
NO20055616L (no) 2006-01-25
ZA200508467B (en) 2006-09-27
EP1617818A1 (en) 2006-01-25
AU2004234003A1 (en) 2004-11-11
JP2006525345A (ja) 2006-11-09
CN1794975A (zh) 2006-06-28
NO20055616D0 (no) 2005-11-28

Similar Documents

Publication Publication Date Title
Dakal et al. Mechanistic basis of antimicrobial actions of silver nanoparticles
Lkhagvajav et al. Antimicrobial activity of colloidal silver nanoparticles prepared by sol-gel method
Elizabeth et al. ZnO nanoparticle incorporated nanostructured metallic titanium for increased mesenchymal stem cell response and antibacterial activity
BRPI0413317A (pt) composição em emulsão
PE20000632A1 (es) Formulaciones de ziprasidona
BRPI0416239A (pt) método para preparar partìculas de submìcron de paclitaxel
AR048356A1 (es) Composiciones que brindan beneficios visuales a la piel con atributos opticos especificos
Wu et al. In vitro cytotoxicity of Cu2+, Zn2+, Ag+ and their mixtures on primary human endometrial epithelial cells
ATE431131T1 (de) Meloxican-formulierungen in nanoteilchenform
BRPI0408382A (pt) composição contendo materiais de zinco particulado que têm um tamanho definido de cristalito
BRPI0519088A2 (pt) formulaÇÕes de tacrolimo nanoparticuladas
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
Hamlekhan et al. Fabrication of drug eluting implants: study of drug release mechanism from titanium dioxide nanotubes
BRPI0406944A (pt) Composição para higiene pessoal contendo partìculas com formato irregular e partìculas esféricas
BRPI0419048A (pt) composição útil para fornecer revestimento de remoção de nox sobre a superfìcie material
EP2316895B8 (en) Self-cleaning water-based coating compositions, and self-cleaning member
BR0309894A (pt) Composição, processo para preparar uma composição de celulose microcristalina, produto alimentìcio, composição farmacêutica, composição cosmética, forma de dosagem farmacêutica, e, composição industrial
PL1713446T3 (pl) Nielamelarne trójskładnikowe kompozycje lipidów
BRPI9711856B8 (pt) métodos para preparação de um agente ativo, substancialmente insolúvel em água e composição para liberação in vivo de um agente ativo
BR0315215A (pt) Composições antifúngicas em partìculas sólidas para uso farmacêutico
WO2007141344A3 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
BRPI0409929A (pt) formulação para tornar uma droga antimicrobiana potente contra organismos normalmente considerados serem resistentes à droga
BRPI0507342A (pt) sólidos supersaturados estabilizados de fármacos lipofìlicos
WO2007059515A3 (en) Compositions of lipoxygenase inhibitors
AU2002334939A1 (en) Compositions having a combination of particles for immediate release and for controlled release

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.